Mach 1 Financial Group LLC Purchases 631 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mach 1 Financial Group LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 107.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,216 shares of the biopharmaceutical company’s stock after purchasing an additional 631 shares during the period. Mach 1 Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,068,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $37,000. Finally, Sutton Wealth Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,353,323.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,195 shares of company stock worth $9,759,898. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.2 %

REGN stock traded down $1.82 during mid-day trading on Tuesday, reaching $890.66. The company had a trading volume of 627,942 shares, compared to its average volume of 491,369. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market capitalization of $97.76 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. The firm has a 50 day moving average of $945.77 and a 200 day moving average of $895.19. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the firm earned $10.96 EPS. The company’s revenue for the quarter was up .6% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

REGN has been the topic of several research analyst reports. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Truist Financial reiterated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.